Literature DB >> 15768343

Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.

Markus Backmund1, Jens Reimer, Kirsten Meyer, J Tilman Gerlach, Reinhart Zachoval.   

Abstract

Injection drug users (IDUs) are the largest group of persons infected with hepatitis C virus (HCV), with a prevalence of 50%-90%. The transmission of HCV is not the effect of the drug injected but of sharing contaminated equipment. For the sake of prevention, we have to know which factors are more likely to lead to HCV seroconversion and which particular situations and environments are risk factors for equipment sharing. As far as therapy is concerned, some studies have shown that treatment for HCV infection in IDUs during substitution treatment for drug dependency is as successful as is treatment of patients who are not IDUs. Screening and early treatment of IDUs could play an important role in controlling HCV infection. The rate of reinfection may not as high as supposed. All studies dealing with treatment for HCV infection in IDUs have stressed the necessity of collaboration among hepatologists and specialists in addiction medicine, social workers, and psychotherapists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15768343     DOI: 10.1086/427475

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

1.  Injection drug users: the overlooked core of the hepatitis C epidemic.

Authors:  Brian R Edlin; Michael R Carden
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

2.  Hepatitis C, illicit drug use and public health: does Canada really have a viable plan?

Authors:  Benedikt Fischer; Kate Kalousek; Jürgen Rehm; Jeff Powis; Mel Krajden; Jens Reimer
Journal:  Can J Public Health       Date:  2006 Nov-Dec

3.  Estimating HCV prevalence at the state level: a call to increase and strengthen current surveillance systems.

Authors:  Rachel Hart-Malloy; Alvaro Carrascal; A Gregory Dirienzo; Colleen Flanigan; Kristi McClamroch; Lou Smith
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

Review 4.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

5.  Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.

Authors:  Ashly E Jordan; Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Denis Nash; David C Perlman
Journal:  Drug Alcohol Depend       Date:  2015-04-13       Impact factor: 4.492

6.  Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?

Authors:  Dimitra Panagiotoglou; Emanuel Krebs; Jeong Eun Min; Michelle Olding; Keith Ahamad; Lianping Ti; Julio S G Montaner; Bohdan Nosyk
Journal:  Int J Drug Policy       Date:  2017-06-01

7.  Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users.

Authors:  William A Zule; Elizabeth C Costenbader; Curtis M Coomes; Wendee M Wechsberg
Journal:  Am J Public Health       Date:  2009-02-12       Impact factor: 9.308

Review 8.  Controversies in and challenges to our understanding of hepatitis C.

Authors:  Robert G Batey
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742

9.  A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.

Authors:  Marie Jauffret-Roustide; Yann Le Strat; Elisabeth Couturier; Damien Thierry; Marc Rondy; Martine Quaglia; Nicolas Razafandratsima; Julien Emmanuelli; Gaelle Guibert; Francis Barin; Jean-Claude Desenclos
Journal:  BMC Infect Dis       Date:  2009-07-16       Impact factor: 3.090

10.  Socio-demographic and clinical features of Irish iatrogenic hepatitis C patients: a cross-sectional survey.

Authors:  Olivia McKenna; Caitriona Cunningham; Catherine Blake
Journal:  BMC Public Health       Date:  2009-09-07       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.